CROISSY-BEAUBOURG, France--(BUSINESS WIRE)--Regulatory News:
THERADIAG (ISIN: FR0004197747, ticker: ALTER) (Paris:ALTER), a company specialising in in vitro diagnostics and theranostics, announces the publication of a large number of abstracts on the benefits of biotherapy monitoring during the annual Congress of the European Crohn’s and Colitis Organisation (ECCO), which focuses on Inflammatory Bowel Diseases (Crohn’s disease and ulcerative colitis), and which was held in Vienna on February 14-17, 2018.
Growing use of monitoring kits
During this 13th Congress of ECCO, over 90 publications presented data on biotherapy monitoring, of which approximately 20 provided results of studies conducted with Lisa Tracker® kits1, thereby confirming the scientific community’s keen interest for biotherapy monitoring. Furthermore, this growing number of publications reflects the increasing use of monitoring kits, in a number of centres that is also rising continuously.
Lisa Tracker® remains the most comprehensive range on the market, able to monitor all gastroenterology patients.
Confirmation and reinforcement of the results obtained for Vedolizumab monitoring
A total of 8 abstracts presenting the results for Vedolizumab (EntyvioTM) monitoring using Lisa Tracker® tests confirmed the correlation between drug serum levels and clinical response, both for induction and for maintenance (long-term) therapy. These results were also used to define the therapeutic threshold.
“Data presented during the Congress of ECCO 2018 reinforces the use of biotherapy tests and confirms once again the reliability of our tests and the interest of the scientific community. The growing number of abstracts reflects the increasing use of monitoring tests, which we welcome as it improves the treatment of IBD patients,” comments Prof Gérard Tobelem, Chairman of Theradiag’s Board of Directors. “With our Lisa Tracker® monitoring range, we are the only company on the market to cover all gastroenterology patients.”
Links to the presented abstracts:
Capitalizing on its expertise in the distribution, development and
manufacturing of in vitro diagnostic tests, Theradiag innovates and
develops theranostics tests (combining treatment and diagnosis) that
measure the efficiency of biotherapies in the treatment of autoimmune
diseases, cancer and AIDS. Theradiag is thus participating in the
development of customized treatment, which favors the individualization
of treatments, the evaluation of their efficacy and the prevention of
drug resistance. Theradiag notably markets the Lisa Tracker® range (CE
marked), which is a comprehensive multiparameter theranostic solution
for patients with autoimmune diseases treated with biotherapies. The
Company is based in Marne-la-Vallée, near Paris, and has over
For more information about Theradiag, please visit our website: www.theradiag.com
1 The studies were conducted in numerous centres, including the University Hospitals of Lausanne (Switzerland), and of Saint-Etienne, Nancy, and Le Kremlin Bicêtre (France), McGill University, Montreal (Canada), and Columbus State University, Georgia (USA).